secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001493152-24-028352
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem acquires Solosec from Lupin for up to $84M in contingent consideration
-----------------------------------------------------------------------------

- Evofem (OTCQB: EVFM) acquired Solosec (secnidazole) from Lupin Inc.; deal closed July 14, 2024.
- Potential total consideration up to $84 million based on future contingent milestones; plus assumption of certain liabilities.
- Solosec is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
- Acquisition complements Evofem's women's health portfolio, which includes Phexxi; Evofem also in merger with Aditxt (ADTX).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224028352/0001493152-24-028352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224028352/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer